Progress in the treatment of bone metastases in cancer patients

Bibliography

• Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55(1):61-6
   PubMed Web of Science ®Google Scholar
• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27(3):165-76
   PubMed Web of Science ®Google Scholar
• Crockett JC, Rogers MJ, Coxon FP, Bone remodelling at a glance. J Cell Sci 2011;124(Pt 7):991-8
   PubMed Web of Science ®Google Scholar
• Crockett JC, Mellis DJ, Scott DI, Helfrich MH. New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. Osteoporos Int 2011;22(1):1-20
   PubMed Web of Science ®Google Scholar
• Kodama H, Nose M, Niida S, Yamasaki A. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med 1991;173(5):1291-4
   PubMed Web of Science ®Google Scholar
• Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann NY Acad Sci 2008;1143:123-50
   PubMed Web of Science ®Google Scholar
• Arai F, Miyamoto T, Ohneda O, Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999;190(12):1741-54
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89(2):309-19
   PubMed Web of Science ®Google Scholar
• Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350(16):1655-64
   PubMed Web of Science ®Google Scholar
• Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19(1):18-54
   PubMed Web of Science ®Google Scholar
• DePuy V, Anstrom KJ, Castel LD, Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007;15(7):869-76
   PubMed Web of Science ®Google Scholar
• Sathiakumar N, Delzell E, Morrisey MA, Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Res Treat 2012;1:231-8
   Google Scholar
• Sathiakumar N, Delzell E, Morrisey MA, Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011;14(2):177-83
   PubMed Web of Science ®Google Scholar
• Yong M, Jensen AO, Jacobsen JB, Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat 2011;129(2):495-503
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD, The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16(4):579-84
   PubMed Web of Science ®Google Scholar
• Russell RG, Xia Z, Dunford JE, Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci 2007;1117:209-57
   PubMed Web of Science ®Google Scholar
• Roelofs AJ, Thompson K, Ebetino FH, Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2011;16(27):2950-60
   Web of Science ®Google Scholar
• Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12(20 Pt 2):6222s-30s
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Theriault RL, Lipton A, Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16(6):2038-44
   PubMed Web of Science ®Google Scholar
• Theriault RL, Lipton A, Hortobagyi GN, Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17(3):846-54
   PubMed Web of Science ®Google Scholar
• Lipton A, Theriault RL, Hortobagyi GN, Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88(5):1082-90
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel IJ, Lichinitser MR, Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14(9):1399-405
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel IJ, Lichinitzer M, Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90(6):1133-7
   PubMed Web of Science ®Google Scholar
• Paterson AH, Powles TJ, Kanis JA, Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11(1):59-65
   PubMed Web of Science ®Google Scholar
• Kristensen B, Ejlertsen B, Groenvold M, Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999;246(1):67-74
   PubMed Web of Science ®Google Scholar
• Kohno N, Aogi K, Minami H, Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23(15):3314-21
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98(8):1735-44
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon DH, Dugan W Jr, Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100(1):36-43
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005(3):CD003474
   Google Scholar
• Dearnaley DP, Sydes MR, Mason MD, A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95(17):1300-11
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-68
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96(11):879-82
   PubMed Web of Science ®Google Scholar
• Small EJ, Smith MR, Seaman JJ, Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21(23):4277-84
   PubMed Web of Science ®Google Scholar
• Yuen KK, Shelley M, Sze WM, Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006(4):CD006250
   PubMed Web of Science ®Google Scholar
• Heras P, Karagiannis S, Kritikos K, Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. Eur J Cancer Care (Engl) 2007;16(6):539-42
   PubMed Web of Science ®Google Scholar
• Piga A, Bracci R, Ferretti B, A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res 1998;17(2):213-17
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS, Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100(12):2613-21
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S, Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial–the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21(16):3150-7
   PubMed Web of Science ®Google Scholar
• Carteni G, Bordonaro R, Giotta F, Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist 2006;11(7):841-8
   PubMed Web of Science ®Google Scholar
• Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008;74(11):1385-93
   PubMed Web of Science ®Google Scholar
• Bamias A, Kastritis E, Bamia C, Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23(34):8580-7
   PubMed Web of Science ®Google Scholar
• Saad F, Brown JE, Van Poznak C, Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol [Epub ahead print]
   Web of Science ®Google Scholar
• Sutjandra L, Rodriguez RD, Doshi S, Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet 2011;50(12):793-807
   PubMed Web of Science ®Google Scholar
• Lipton A, Steger GG, Figueroa J, Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25(28):4431-7
   PubMed Web of Science ®Google Scholar
• Brown JE, Cook RJ, Major P, Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97(1):59-69
   PubMed Web of Science ®Google Scholar
• Brown JE, Thomson CS, Ellis SP, Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003;89(11):2031-7
   PubMed Web of Science ®Google Scholar
• Coleman RE, Major P, Lipton A, Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23(22):4925-35
   PubMed Web of Science ®Google Scholar
• Fizazi K, Lipton A, Mariette X, Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27(10):1564-71
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377(9768):813-22
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29(9):1125-32
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2011;28(35):5132-9
   Web of Science ®Google Scholar
• Lipton A, Siena S, Rader M. Comparison of denosumab versus zoledronic acid for treatment of bone metastases in advanced cancer patients: An integrated analysis of 3 pivotal trials [abstract 1249P]. The 35th ESMO Congress 2010; Milan, Italy; 2010
   Google Scholar
• Henriksen G, Fisher DR, Roeske JC, Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003;44(2):252-9
   PubMed Web of Science ®Google Scholar
• Nilsson S, Larsen RH, Fossa SD, First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11(12):4451-9
   PubMed Web of Science ®Google Scholar
• Nilsson S, Franzen L, Parker C, Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8(7):587-94
   PubMed Web of Science ®Google Scholar
• Battistini B, Chailler P, D'Orleans-Juste P, Growth regulatory properties of endothelins. Peptides 1993;14(2):385-99
   PubMed Web of Science ®Google Scholar
• Nelson JB, Nguyen SH, Wu-Wong JR, New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999;53(5):1063-9
   PubMed Web of Science ®Google Scholar
• Nelson JB, Chan-Tack K, Hedican SP, Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56(4):663-8
   PubMed Web of Science ®Google Scholar
• Carducci MA, Saad F, Abrahamsson PA, A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110(9):1959-66
   PubMed Web of Science ®Google Scholar
• James ND, Caty A, Borre M, Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009;55(5):1112-23
   PubMed Web of Science ®Google Scholar
• James ND, Caty A, Payne H, Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 2010;106(7):966-73
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010;36(2):177-84
   PubMed Web of Science ®Google Scholar
• Yu EY, Wilding G, Posadas E, Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;15(23):7421-8
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Zhu X, Zarnegar R, Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147(2):386-96
   PubMed Web of Science ®Google Scholar
• Hussein MA, Smith MR, Sweeney C, Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial [abstract # 4516]. Annual Meeting of American Society of Clinical Oncology; 2011
   Google Scholar
• AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal > 5 years. Oncology (Williston Park) 2011;25(12):1212-13
   PubMedGoogle Scholar
• Coleman RE, Marshall H, Cameron D, Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365(15):1396-405
   PubMed Web of Science ®Google Scholar
• Yan T, Yin W, Zhou Q, The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 2012;48(2):187-95
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Stoeger H, Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011;12(7):631-41
   PubMed Web of Science ®Google Scholar